The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Open accessAbstract
BACKGROUND: Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recurrence after radical resection. Whether the use of mitotane is beneficial as an adjuvant treatment has been controversial. Our aim was to evaluate the efficacy of adjuvant mitotane in prolonging recurrence-free survival. METHODS: We performed a retrospective analysis involving 177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in Germany between 1985 and 2005. Adjuvant mitotane was administered to 47 Italian patients after radical surgery (mitotane group), whereas 55 Italian patients and 75 German patients (control groups 1 and 2, respectively) did not receive adjuvant treatment after surgery. RESULTS: Baseline features in the mitotane group and the control group from Italy were similar; the German patients were significantly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in the mitotane group. Recurrence-free survival was significantly prolonged in the mitotane group, as compared with the two control groups (median recurrence-free survival, 42 months, as compared with 10 months in control group 1 and 25 months in control group 2). Hazard ratios for recurrence were 2.91 (95% confidence interval [CI], 1.77 to 4.78; P<0.001) and 1.97 (95% CI, 1.21 to 3.20; P=0.005), respectively. Multivariate analysis indicated that mitotane treatment had a significant advantage for recurrence-free survival. Adverse events associated with mitotane were mainly of grade 1 or 2, but temporary dose reduction was needed in 13% of patients. CONCLUSIONS: Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
Dackiw, A. P. B., Lee, J. E., Gagel, R. F., & Evans, D. B. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0030-7 · Cited by 387
Schulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366
An eleven-year experience with adrenocortical carcinoma.
Pommier, R. F., & Brennan, M. F. (1992) · PubMed · Cited by 332
Haak, H., Hermans, J., van de Velde, C., Lentjes, E., Goslings, B., Fleuren, G.-J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.941 · Cited by 312
Berruti, A., Terzolo, M., Sperone, P., Pia, A., Della Casa, S., Gross, D. J., Carnaghi, C., Casali, P., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Self-citationGicquel, C., BERTAGNA, X. Y., Gaston, V., Coste, J., Louvel, A., Baudin, É., Bertherat, J. Y., Chapuis, Y., Duclos, J. M., Schlumberger, M. J., et al. (2001) · PubMed · Cited by 285
Macfarlane, D. A. (1958) · PubMed · Cited by 263
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma
Fassnacht, M., Hahner, S., Polat, B., Koschker, A.-C., Kenn, W., Flentje, M., & Allolio, B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1007 · Cited by 259
Self-citationSullan, M., Boileau, M., & Hodges, C. V. (1978) · Journal of Urology · doi:10.1016/s0022-5347(17)57317-6 · Cited by 255
Baudin, E., Pellegriti, G., Bonnay, M., Penfornis, A., Laplanche, A., Vassal, G., & Schlumberger, M. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2 · Cited by 239
Bellantone, R., Ferrante, A., Boscherini, M., Lombardi, C. P., Crucitti, P., Crucitti, F., Favia, G., Borrelli, D., Boffi, L., Capussotti, L., et al. (1997) · Surgery · doi:10.1016/s0039-6060(97)90229-4 · Cited by 210
Adrenocortical carcinoma: Clinical outcome at the end of the 20th century
Vassilopoulou-Sellin, R., & Schultz, P. N. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1113::aid-cncr1428>3.0.co;2-i · Cited by 160
Mitotane for adrenocortical carcinoma treatment.
Hahner, S., & Faßnacht, M. (2005) · PubMed · Cited by 156
Self-citationAdrenal cortical carcinoma--a continuing challenge.
Dj, H., van Heerden, J. A., Cs, G., Carney, J. A., & Carpenter, P. C. (1983) · PubMed · Cited by 156
The Cleveland Clinic experience with adrenal cortical carcinoma
Bodie, B., Novick, A. C., Pontes, J. E., Straffon, R. A., Montie, J. E., Babiak, T., Sheeler, L., & Schumacher, P. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)40734-8 · Cited by 145
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
Vassilopoulou‐Sellin, R., Klein, M. J., Schultz, P. N., Samaan, N. A., Guinee, V. F., Taylor, S. H., & Hess, K. R. (1993) · Cancer · doi:10.1002/1097-0142(19930515)71:10<3119::aid-cncr2820711037>3.0.co;2-8 · Cited by 126
Treatment of Adrenal Carcinomas
SCHTEINGART, D. E. (1982) · Archives of Surgery · doi:10.1001/archsurg.1982.01380330010004 · Cited by 118
Surgical management, DNA content, and patient survival in adrenal cortical carcinoma
Lee, J. E., Berger, D. H., El‐Naggar, A. K., Hickey, R. C., Vassilopoulou‐Sellin, R., Gagel, R. F., Burgess, M. A., & Evans, D. B. (1995) · Surgery · doi:10.1016/s0039-6060(05)80119-9 · Cited by 115
Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope
Kirschner, L. S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1739 · Cited by 107
Adrenocortical Carcinoma: Experience in 45 Patients
Barzon, L., Fallo, F., Sonino, N., Daniele, O., & Boscaro, M. (2009) · Oncology · doi:10.1159/000227608 · Cited by 83
Dickstein, G., Shechner, C., Arad, E., Best, L., & Nativ, O. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5113 · Cited by 74
Clinical results of the use of mitotane for adrenocortical carcinoma
Kasperlik-Zaluska, A. A. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000001000008 · Cited by 65
Venkatesh (1989) · doi:10.1002/1097-0142(19890801)64:3
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Kasperlik-Załuska (1995) · doi:10.1002/1097-0142(19950515)75:10<2587::aid-cncr2820751028>3.0.co;2-5
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citation
Metadata
- Authors
- Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., Reimondo, G., Bollito, E., Papotti, M., Saeger, W., Hahner, S., Koschker, A.-C., Arvat, E., Ambrosi, B., Loli, P., Lombardi, G., Mannelli, M., Bruzzi, P., Mantero, F., Allolio, B., Dogliotti, L., & Berruti, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-07
- Volume
- 356
- Issue
- 23
- Pages
- 2372-2380
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164015349
- Cited by
- 764
- References
- 32
- FWCI
- 40.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.